Parallax Volatility Advisers
AVDL

Parallax Volatility Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

Parallax Volatility Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$716 – 2715
2022
Q4 		$716 Buy
+100
New +$701 ﹤0.01% 2760
2018
Q2 		– Sell
-22,000
Closed -$160K – 2104
2018
Q1 		$160K Buy
+22,000
New +$194K ﹤0.01% 1291

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parallax Volatility Advisers's AVDL Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 14,549 shares — an estimated $153K sold.

Parallax Volatility Advisers first reported a position in AVDL in Q1 2018 and held it in 6 quarters. The position peaked at $153K in Q4 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Parallax Volatility Advisers reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 14,549 Avadel Pharmaceuticals shares in Q1 2025, an estimated $153K.
  • Parallax Volatility Advisers first reported a position in Avadel Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • Parallax Volatility Advisers's Avadel Pharmaceuticals position peaked at $153K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.